BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17119107)

  • 1. Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.
    Chavez B; Poveda RA
    Ann Pharmacother; 2006 Dec; 40(12):2265-8. PubMed ID: 17119107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials.
    Hoffmann VP; Case M; Stauffer VL; Jacobson JG; Conley RR
    J Clin Psychopharmacol; 2010 Dec; 30(6):656-60. PubMed ID: 21105275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
    Charpeaud T; Samalin L; Llorca PM
    Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report.
    Saatcioglu O; Gumus S; Kamberyan K; Yanik M
    Psychopharmacol Bull; 2010; 43(4):70-2. PubMed ID: 21240152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
    Chen CH; Huang MC; Lu ML
    J Clin Psychopharmacol; 2007 Oct; 27(5):516-7. PubMed ID: 17873689
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
    Kasteng F; Eriksson J; Sennfält K; Lindgren P
    Acta Psychiatr Scand; 2011 Sep; 124(3):214-25. PubMed ID: 21609324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia.
    Wisniewski CS; Robert S
    Ann Pharmacother; 2012; 46(7-8):1097-104. PubMed ID: 22811346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.
    Pawelczyk T; Pawelczyk A; Rabe-Jablonska J
    J Psychiatr Pract; 2014 Jul; 20(4):301-7. PubMed ID: 25036587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching and combining antipsychotics.
    Correll CU
    CNS Spectr; 2010 Apr; 15(4 Suppl 6):8-11. PubMed ID: 21141654
    [No Abstract]   [Full Text] [Related]  

  • 16. Aripiprazole for the management of olanzapine-induced weight gain.
    Englisch S; Weinbrenner A; Inta D; Zink M
    Pharmacopsychiatry; 2009 Jul; 42(4):166-7. PubMed ID: 19585397
    [No Abstract]   [Full Text] [Related]  

  • 17. Aripirazole-olanzapine combination for treatment of schizophrenia.
    Duggal HS
    Can J Psychiatry; 2004 Feb; 49(2):151. PubMed ID: 15065751
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination loxapine and aripiprazole for refractory hallucinations in schizophrenia.
    Sokolski KN
    Ann Pharmacother; 2011 Jul; 45(7-8):e36. PubMed ID: 21672885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report.
    Boland X; Chhabra P
    J Psychiatr Pract; 2019 Mar; 25(2):135-138. PubMed ID: 30849062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee JH; Lee YH; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2009; 32(5):243-9. PubMed ID: 19620849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.